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REVIEW ARTICLE
Atomoxetine for Attention Deficit Hyperactivity Disorder in Children
and Adolescents with Autism: A Systematic Review and Meta-Analysis
Q1
Q3
Suravi Patra , Naresh Nebhinani, Anand Viswanathan, and Richard Kirubakaran
Atomoxetine is prescribed to children with autism spectrum disorder having symptoms of attention deficit hyperactivity
disorder. We sought to examine the efficacy and safety of atomoxetine in this population. After screening for inclusion cri-
teria, we identified three randomized placebo controlled trials involving 241 children. We assessed internal validity using
standard Cochrane Risk of bias tool for randomized controlled trials (RCTs). We used Revman 5.3 for meta-analysis and
GRADE approach to create summary of findings with grading of the quality of evidence. Atomoxetine had a benefit on
improving parent-rated hyperactivity (standardized mean difference [SMD] = −0.73, 95% Confidence Interval, CI = −1.15
to −0.34) and parent-rated inattention (SMD = −0.53, 95% CI = −0.93 to −0.12) but the magnitude of effects is uncertain.
However, atomoxetine was also associated with increased risk of non-serious adverse effects like nausea and vomiting,
decreased sleep, and decreased appetite. Atomoxetine may be effective in improving hyperactivity and inattention in chil-
dren with autism spectrum disorder and attention deficit hyperactivity disorder. However, we are uncertain about the true
effect of this intervention and need more RCTs trials designed to evaluate this. Autism Research 2018. © 2018 Interna-
tional Society for Autism Research, Wiley Periodicals, Inc.
Lay Summary: Atomoxetine is prescribed for Attention Deficit Hyperactivity Disorder (ADHD). About a third of children
and adolescents with autism also suffer from ADHD. We carried out an analysis of data reported from a specific kind of
medication trials which had examined the effectiveness and side effects of atomoxetine in this patient population. We
could find only three such trials and analyzed the reported data. Our analysis revealed that atomoxetine is effective in
improving symptoms of ADHD like hyperactivity and inattention and also causes side effects like nausea, vomiting,
decreased sleep, and decreased appetite. However, the existing data are insufficient to provide a conclusive statement
with certainty and more trials are needed for this.
Keywords: autism; pervasive developmental disorder; attention deficit/hyperactivity disorder; meta-analysis; atomoxetine
Introduction
Autism Spectrum Disorder (ASD) is an early onset neuro-
developmental disorder marked by impaired capacity of
socialization, communication, and restricted stereotyped
range of behavior. A large number of children with ASD
exhibit symptoms of Attention Deficit Hyperactivity Dis-
order (ADHD). DSM5 has allowed comorbid diagnosis of
ADHD with ASD hence changing the existing nosological
convention wherein ADHD symptoms were assumed sec-
ondary to underlying ASD [American Psychiatric Associa-
tion, APA; 2013]. ADHD is the third common co-
morbidity and is diagnosed in 37–85% of children with
ASD [Gadow, DeVincent, & Pomeroy, 2006; Leyfer et al.,
2006]. Co-morbid ADHD often results in lower cognitive,
adaptive, and social functioning [RaoQ4 , 2014; Yerys et al.,
2009]. Also, about 20–60% of children with ADHD have
social difficulties similar to autism higher than typically
developing (TD) children [Grzadzinski, Dick, Lord, &
Bishop, 2016]. There still remains confusion regarding
ADHD or autism as the cause of these social difficulties.
Impulsivity which is a core symptom of ADHD might
contribute to inappropriate intrusiveness; however, even
after treatment of ADHD social difficulties in getting
along with friends and siblings and expressing affection
persist [Grzadzinski et al., 2011]. In addition to symptom
overlap; ADHD and ASD share biological and neuropsy-
chological risk factors [Taurines et al., 2012]. Causal and
mediational analyses have identified multiple pathways
between ASD and ADHD with specific targets for inter-
ventions [Sokolova et al., 2017].
Children having co-morbid ADHD and ASD are under-
stood as a distinct phenotype needing special intervention
strategies [Craig, 2015]. As in TD children, medications are
effective in treatment of symptoms of ADHD. Stimulants
are among the most commonly prescribed medications;
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however, treatment response is lower and is often associ-
ated with more adverse effects [Bachmann, Manthey,
Kamp-Becker, Glaeske, &Hoffmann, 2013; Kim et al., 2017;
RUPP., 2005]. Stimulants can exacerbate stereotypies, tics,
self-injury, and anxiety in children with ASD [Aman et al.,
2008; Arnold et al., 2006; Gadow et al., 2005].
Atomoxetine, a non-stimulant medication, is consid-
ered second-line alternative in managing ADHD in chil-
dren with ASD. Atomoxetine acts as a highly specific
presynaptic noradrenaline reuptake inhibitor in the pre-
frontal cortex, the region for attention and other higher
cognition processes. It increases the availability of dopa-
mine in prefrontal cortex but does not have any direct
activity on dopamine. It does not have action on striatum
or midbrain hence is free from addictive potential, stereo-
typies, and tics [Barton, 2005]. It can be used in case of
stimulant failure or intolerance and in presence of co-
morbidities like tic and anxiety disorders because of bet-
ter tolerability and safety [Kohn, Tsang, & Clarke,
2012]. The long half-life of atomoxetine makes it effec-
tive throughout the day with a single daily dose. Standard
dose range recommended for atomoxetine is 0.5–
1.8 mg/kg/day. Four to six weeks of treatment is needed
for optimal of efficacy with atomoxetine [Clemow, 2014].
Stimulants are the second most commonly prescribed
medications in children with ASD and ADHD across the
world except in the UK. In UK methylphenidate is the
most commonly prescribed medication [Hsia et al.,
2014]. In a four continent study involving 10 countries,
prescription rates of ADHD medications have risen in the
United States and European countries like Denmark,
Netherlands, and Spain. Initiation of ADHD medication
in ADHD with ASD is much earlier than in ADHD chil-
dren. Of the children and adolescents with ASD, 16% are
prescribed with stimulants and atomoxetine [Dalsgaard,
Nielsen, & Simonsen, 2013]. In the United States, 56%
children with ASD are prescribed with ADHD medica-
tions of which stimulants are the third most common
medications. With 8% prescription rates, atomoxetine
was the second most common medication among ADHD
medications [Williams et al., 2012].
The variation in prescription practices is due to inconsis-
tent treatment guidelines, differences in healthcare systems,
and inadequate evidence base of psychopharmacological
agents. Systematic reviews conducted by rigorous Cochrane
methodology are instrumental in shaping treatment guide-
lines; hence it is imperative to estimate the efficacy and
safety of these psychopharmacological agents.
Many clinical trials have demonstrated that atomoxe-
tine is effective and safe in children with ASD [Aman,
2014; Reichow, 2013]. To our knowledge only three ran-
domized controlled trials have been published demon-
strating effectiveness and safety of atomoxetine in ASD
[Arnold, 2006; Harfterkamp et al., 2012; Handen et al.,
2015]. First of these randomized controlled trials (RCTs)
was a double-blind placebo controlled cross over trial of
6 weeks involving 16 subjects which failed to show clini-
cally significant benefit with atomoxetine [Arnold, 2006].
In the second trial of 8 weeks duration involving 97 par-
ticipants, 20.9% participants on atomoxetine improved
much or very much on Clinical Global Improvement
(CGI-I) scale as compared to 8.7% on placebo [Harfter-
kamp, 2012]. The third parallel group four arm RCT
involving atomoxetine, placebo, and parent training was
of 10 weeks duration in which 46.9% of participants on
atomoxetine showed 30% improvement in Swanson,
Nolan and Pelham (SNAP) scores as compared to 19.4%
on placebo. Two trials reported of serious side effects
whereas all three trials reported non-serious side effects.
Two reviews have examined usefulness of Atomoxetine in
ADHD co-morbid with ASD [Reichow, 2013; Aman, 2014].
These reviews have not reported inattention andhyperactiv-
ity/impulsivity as separate outcomes. The magnitude of side
effects was also not reported. The reviews were not carried
out using Cochrane methodology or Preferred Reporting
Items for Systematic reviews and Metaanalysis (PRISMA)
guidelines. Risk of bias and quality of trials were also not
addressed by these reviews.
To address these flaws, we carried out a systematic
review and meta-analysis using Cochrane guidelines for
estimation of risk of bias and GRADE approach for evalu-
ation of quality of trials and report on efficacy and safety
of atomoxetine in children with ASD.
Methods
Search Strategy for Identification of Studies
Three reviewers independently searched Pubmed,
Cochrane central register of controlled trials, Cochrane
library, Embase, and ClinicalTrials.gov upto April 2018. For
Pubmed we used the search strategy: “attention deficit dis-
order with hyperactivity” (Mesh) AND “autistic disorder”
(Mesh) AND “atomoxetine hydrochloride” (Mesh). We
adapted the search terms andmodified according to the dif-
ferent databases. The search terms used for Cochrane library
were: “autistic disorder,” “attention deficit disorder with
hyperactivity,” and “atomoxetine hydrochloride.” For
Embase we used: “attention deficit disorder with
hyperactivity,” “autism,” and “atomoxetine.” For ongoing
studies, we searched in ClincialTrials.gov with the terms
“autism or pervasive developmental disorder” and an inter-
vention filter for “Atomoxetine hydrochloride OR atomox-
etine.” We also searched the reference lists of included
studies, reviews, andmeta-analyses formore citations.
Study Selection
We used the following criteria for selecting studies for
inclusion in this review.















































































































1. Randomized placebo controlled trials comparing ato-
moxetine with placebo.
2. Patient population of children and adolescents of
≤18 years age with diagnosis of ASD as per DSM5 or
Pervasive Developmental Disorder as per DSMIV or
ICD 10.
3. Trials using atomoxetine at standard dose (0.5–1.8mg/kg/
day) andduration 4weeks.
4. Trials reporting ADHD symptoms as outcomemeasures.
We did not include trials involving children with epi-
lepsy or traumatic brain injury.
Outcome Measures
Primary outcomes were parent-rated symptoms of ADHD
(inattention, hyperactivity, or impulsivity) both short-
term (≤6 months) and long-term (≥6 months), social
behavior, and serious adverse events. Parent-rated symp-
toms of ADHD were chosen as primary outcome as
parent-rating of ADHD symptoms is more sensitive than
teacher-rating in children with ASD [RUPP, 2005]. ADHD
symptoms rated on standard scales like SNAP, DSM-IV
rating scale, and ADHD rating scale were included in the
analysis [Swanson, 1983; DuPaul et al., 1998]. Any event
of death, life threatening side effects, prolongation of
hospital stay, or disability was defined as serious adverse
event.
Secondary outcomes were clinician and teacher-rated
ADHD symptoms; overall improvement of ADHD symp-
toms rated on standard scales like CGI-I; parent stress;
quality of life; and non-serious adverse events. Non-
serious adverse events included nausea and vomiting,
decreased appetite, and decreased sleep.
Data Collection and Analysis
Selection of studies. Two review authors SP and NN
independently read the titles and abstracts of the articles
for suitability decision as per the inclusion criteria and
used PRISMA flowchart to present the selection of studies.
SP and NN extracted data from each included study using
standard data extraction forms. We resolved disagree-
ments with discussions and in case of any persisting dis-
agreement, AV acted as arbiter.
Data extraction and management. We extracted
data on details of study design (methods), participants,
intervention, and outcomes. Disagreements were resolved
by discussion and in case of any difficulty we took the
third reviewer’s help. We contacted study authors for
missing data. SP entered the data into Review Manager
5.3 after cross verifying the extracted data against the
included studies.
We extracted the 2 × 2 table values for dichotomous
outcomes like serious adverse events, non-serious adverse
events, and CGI scores. For continuous outcomes
like hyperactivity and inattention, we extracted mean,
standard deviation, and the total number of participants
randomized in the group.
Assessment of risk of bias in included studies. SP
and NN independently assessed for internal validity of
each included study using the Cochrane risk of bias tool
for RCT. There were six domains: random sequence gen-
eration (selection bias), allocation concealment (selection
bias), blinding of participants (performance bias), blind-
ing of outcomes assessor (detection bias), incomplete out-
come data (attrition bias), and selective outcome
reporting (reporting bias) and other biases. We assigned
risk of bias as high, low, or unclear as per the guidelines
provided in Cochrane Handbook of systematic reviews
[Higgins, 2011]. We contacted the trial authors in case of
any discrepancy or lack of clarity in reporting and also
held discussions among the reviewers to clarify any
disagreements.
We created risk of bias graph to explain each domain
individually and summary figure for the overall domains.
Measures of treatment effect. We combined results of
studies reporting effect on symptoms of ADHD using
random-effects model. We chose this model due to its
nature of assuming both within and between-study varia-
tions while pooling the data. Continuous data were
either pooled by calculating mean difference between
groups with 95% CI or SMD along with 95% CI when
same outcomes were measured using different tools.
For dichotomous data we calculated Risk Ratio as pro-
portion of patients experiencing events in the treatment
group divided by proportion of patients experiencing
events in control group.
We analyzed all the homogenous data using Revman5.3
and also calculated the pooled estimates with 95% CI.
Unit of analysis issues. Crossover trials are more prone
to bias owing to carry-over effects, period effects, and
errors in unit of analysis. Our original intent was to
adjust the effect estimates for the unit of analysis error in
crossover trials by conducting a paired analysis. Due to
insufficient data we contacted the trial authors for the
adjusted data or the first period data. However, we did
not get any reply from them; therefore we conducted a
stratified analysis based on the study design.
Assessment of Q73heterogeneity. We examined forest plots for
over lapping confidence interval and using the Chi
square test for heterogeneity keeping significance at 10%
level to detect heterogeneity in studies, and I2 statistic to
detect inconsistency in results which exceeded probabil-
ity due to chance. I2 value of >50% was understood to
denote either moderate or substantial heterogeneity.















































































































Subgroup analysis and investigation of heterogeneity. As
I2 = 0% and chi square < df, we infer that heterogeneity
among included trials was low which could be explained
by chance. So, we did not carry out a subgroup analysis.
Sensitivity Analysis. Since, we have included only two
studies for meta-analysis and the direction of effect esti-
mates are in one side in favor of intervention, we did not
perform the sensitivity analysis.
Assessment of publication bias. We could not do funnel
plot for any analysis to assess publication bias as the
number of studies was too small.
CertaintyQ5 of evidence and summary of findings (SOF) tables.
We have used the GRADEpro software following the
guideline stated in the handbook of GRADE assessment
for creating SOF table. The quality of evidence has four
levels ranging from High, Moderate, Low, to Very Low.
There were five domains to be assessed to arrive at the
quality of evidence: (a) risk of bias, (b) inconsistency,
(c) indirectness, (d) Imprecision, and (e) publication bias.
We judged each domain and assigned the Quality of Evi-
dence for each outcome. We have presented only the
important and critical outcomes in the SOF tables.
Results
Included Studies
We identified 104 records after electronic database
searching and removed duplicates, 93 records were left
which we tested for eligibility. Out of these, we excluded
89 because the trials were either not RCTs, or, population,
intervention or outcomes were not relevant to our review
(Fig. 1). We included three randomized controlled studies
[Arnold et al., 2006; Handen et al., 2015 and Harfterkamp
et al., 2012]. We contacted Arnold et al. and authors of
clinical trials reported in Clinical Trials.gov twice through
email but failed to acquire the raw data.
In the three RCTs, total participants were 241 with
n = 16 in first trial, n = 97 in second trial and (n = 128) in
third trial [Arnold et al., 2006; Handen et al., 2015; Harf-
terkamp et al., 2012]. Girls and boys in the age range
5–17 years were included in the trials. Two of the trials
were carried out in the United States and one in the Neth-
erlands. The trial duration ranged from 6 to 10 weeks.
Handen et al. [2015] was a four-group study in which par-
ticipants were randomized into Atomoxetine, Placebo,
Atomoxetine + Parent Training, and Placebo + Parent
Training groups. We included the first two groups on ato-
moxetine (n = 32) and placebo (n = 32). We did not
include the groups with Parent Training in our analysis
as our aim was to estimate the effect of atomoxetine.
Characteristics of included studies are shown in Table 1.
Risk of Bias Assessment
For all the included studies we used adequatemethod to rule
out selection bias, performance bias, attrition bias, and selec-
tive outcome reporting bias. However, Arnold et al. had to
be judged as high risk of detection bias due to the cross over
design of the study and lack of blinding of outcome assess-
ment. Handen et al. was the only study which was federally
sponsored but was provided atomoxetine by pharmaceuti-
cals hence was rated having low risk of bias. The other two
trials were sponsored by pharmaceuticals manufacturing
atomoxetine hence were rated with unclear risk of bias in
“other risk of bias” category. Pharmaceutical sponsored trials
are known to show higher effect sizes than independent
studies and have industry bias that are beyond standard risk
assessment tools as recently demonstrated in a Cochrane
review [Lundh, 2017]. (Figs. 2 and 3).
Figure 1. Study flow using PRISMA flow diagram.
















































































































Only two trials [Arnold et al., 2006; Handen et al., 2015]
involving 96 participants provided data on parent rated
symptoms of ADHD (inattention and hyperactivity).
Results show beneficial effect of atomoxetine as com-
pared to placebo on parent-rated hyperactivity (SMD
−0.73, 95% CI = −1.15 to −0.34, low quality evidence
(Fig. 4), and parent-rated inattention (SMD −0.53; 95%
CI = −0.93 to −0.12, very low-quality evidence (Fig. 5).
Based on an accepted rule of thumb for interpretation of
effect sizes [Cohen, 1988], SMD of 0.5 and above is gener-
ally suggestive of a moderate effect of intervention. There
was no statistically significant improvement in parent-
rated oppositional behavior or social behavior. There was
no statistically significant improvement in clinician-rated
and teacher-rated ADHD symptoms. Therefore, we are
unclear about the effects of atomoxetine on these
outcomes.
Long Term Symptoms of ADHD
Smith et al. carried out 24-week extension of Handen
et al. trial; open label prescription of atomoxetine. Com-
plex nature of the trial and absence of any other RCT on
long-term efficacy of atomoxetine in ASD with ADHD
precluded meta-analysis.
Serious Adverse Events
Out Q6of three trials involving 193 participants, one serious
adverse event was reported by the cross over RCT [Arnold
et al.] and another by parallel group RCT [Handen et al.].
Arnold et al. reported re-hospitalization of one trial par-
ticipant due to aggressive behavior which they ascribe to
lowering of antipsychotic dose. In the RCT carried out by
Handen et al. one trial participant needed hospitalization
due to seizure caused by suboptimal antiepileptic concen-
trations. Overall risk of serious adverse events was
increased in atomoxetine group (RR 3, 95% CI 0.32 to
27.76, 193 participants low quality evidence); however,
the increase is not statistically significant (Fig. 6).
3.5.1.1.1.. Social behavior. Deficits in social commu-
nication are the hallmark of ASD. Children with ASD
have deficits in social skills and peer interaction. We
wished to see if atomoxetine had any effect on social
skills. As none of the studies reported on social behavior,
no analysis was possible.
Secondary Outcomes
Clinician and teacher-rated symptoms of ADHD.
Harfterkamp et al. used Clinician-rated symptoms on
ADHD RS Q7as the primary outcome variable and Teacher-
rated CTRS was the secondary outcome variable. Handen
et al. used Parent-rated DSMIV (SNAP) as the primary out-
come variable whereas Teacher-rated (SNAP) as the sec-
ondary outcome variable. As only Harfterkamp et al. had
provided clinician-rated scores, pooling of data was not
possible hence meta-analysis could not be done. Harfter-
kamp et al. had presented data as least square means,
hence pooling of data of Handen et al. and Harfterkamp
et al. was not possible.
Table 1. Characteristics of Included Studies
Study N Mean age (range) (years) Gender (%M) Design Length of treatment (weeks) Atomoxetine (mean dose)
Arnold et al. [2006] 16 9.3 (5–15) 75 Crossover 6 44.2 mg/day
Harfterkamp et al. [2012] 97 10.0 (6–17) 86 Parallel 10 1.2 mg/kg/day
Handen et al. [2015]a 64 9.5 (5–14) 80 Parallel, four arm 10 1.8 mg/kg/day
aOnly two study arms which met inclusion criteria were included in our meta-analysis.
Figure 2. Risk of bias summary: Review authors’ judgments
about each risk of bias item for each included study.















































































































Figure 3. Risk of bias graph: Review authors’ judgments about each risk of bias item presented as percentages across all included
studies.
Figure 4. Forest plot, outcome estimate: hyperactivity-parent rated.
Figure 5. Forest plot, outcome estimate: Inattention-parent rated.















































































































Overall improvement of ADHD symptoms. All the
three trials involving 193 participants provided data for
effect of atomoxetine on overall symptoms of ADHD
rated on CGI-I (RR 2.37, 95% CI 1.38, 4.06). There was
beneficial effect of atomoxetine as compared to placebo
but quality of evidence was low (Fig. 7).
Non-serious adverse events. All the three trials
reported significantly higher rates of non-serious adverse
effects like nausea/vomiting, stomach pain, decreased
appetite, and decreased sleep in atomoxetine group. In
addition, symptoms of fatigue, irritability, tiredness,
mood swings, headache, and restlessness were also
reported. Arnold et al. reported significantly higher rates
of fatigue and racing heart rate in atomoxetine group.
Significantly higher rates of fatigue and early morning
awakening were reported by Harfterkamp et al. in the ato-
moxetine group.
Data for non-serious side effects were provided by all
the three included trials involving 193 participants. As
compared to placebo, atomoxetine had a higher risk of
non-serious side effects. RiskQ8 of nausea and vomiting was:
RR 1.91, 95% CI 1.24–2.94, 3 trials, 193 participants,
I2 = 0%, decreased sleep: RR 1.79, 95% CI 1.19–2.70, 3 tri-
als, 193 participants, I2 = 0%, and decreased appetite: RR
1.79, 95% CI 1.17 to 2.73, 3 trials, 193participants,
I2 = 39%, with atomoxetine; the quality of evidence for
all of these outcomes were graded as low (Fig. 8Q9 ).
Higher rates of non-serious side effects might be due to
higher dose of atomoxetine used in the trials. Arnold
et al. used atomoxetine at 1.4 mg/kg/day which is almost
the highest permissible dose; at >1.2 mg/kg/day the effi-
cacy as well as event of non-serious adverse effects
increase [Kohn, 2012].
Parent stress and quality of life. Lecavalier
et al. [2017] described the beneficial effect of atomoxetine
or parent training on parent stress using Parent Stress
Index-Short Form at 10 weeks end point. The authors have
described the change in parent stress evaluated during the
RCT conducted by Handen et al. Although all parents
showed improvement in stress scores, improvement was
not related to atomoxetine or parent training; instead it
was related to treatment response. Authors conclude that
reduction in parent stress levels are more due to placebo
response of regular meeting with research staff than either
medication or parent training. They have also pointed at
need for larger sample size and longer duration of study to
increase the power of the study to detect small effect size
of parent stress. Data from a single RCT precluded meta-
analysis of impact of atomoxetine on parent stress.
None of the included trials reported about quality of
life, hence we could not carry out any analysis. Future
RCTs should consider measuring these outcomes.
Discussion
The results of this meta-analysis demonstrate the benefi-
cial effect of atomoxetine on ADHD symptoms in children
with co-morbid ASD. Atomoxetine is effective in improv-
ing parent rated hyperactivity (SMD −0.73), inattention
(SMD −0.53), and overall symptoms of ADHD (RR 2.37).
The effect size for hyperactivity (SMD −0.73) in our meta-
anaylsis is higher than (SMD = 0.67) reported in TD chil-
dren with ADHD. However, the effect size for inattention
(SMD = 0.53) is lower than (SMD = 0.59) that in TD chil-
dren [Schwartz, 2014]. Atomoxetine is more effective in
reducing symptoms of hyperactivity in children with ASD.
Children with ASD show less response to atomoxetine;
degree of response is inversely proportional to the degree
of severity of autism [Fernandez, 2011, Charnsil, 2011].
Atomoxetine is usually a well-tolerated medicine with
mild adverse effects like headache, pain abdomen, nau-
sea, decreased appetite, and weight loss similar to pla-
cebo. There are only rare incidents of serious adverse
events with atomoxetine. Children with ASD have a
higher risk of developing irritability, decrease in appetite
and nausea as reported in RCTs involving atomoxetine.
Tumuluru et al. reported in detail about the adverse
effects seen during RCT conducted by Handen et al. The
authors report increased incidence of non-serious adverse
events like decreased appetite and fatigue associated with
atomoxetine in children with ASD as compared to TD
children. However, there was no incidence of any serious
adverse events and authors conclude that atomoxetine is
as safe in children with ASD as it is in TD children
[Tumuluru et al., 2017]. As reported by authors of the
Figure 6. Forest plot: Serious adverse events.















































































































RCT, our meta-analysis also did not find significant differ-
ence of serious adverse events in atomoxetine as com-
pared to placebo [Tumuluru et al., 2017]. However, the
rate of non-serious side effects is higher in terms of
higher risk of gastrointestinal side effects; more than two-
third of trial participants experienced decreased appetite
and about 50% patients complained of nausea/vomiting.
About one-third of patients had impaired sleep. Our
findings synthesized the available results of RCTs carried
out till date in this patient population and hence gave an
estimate of higher risk of non-serious side effects as com-
pared to placebo.
Smith et al. allowed continuation of treatment with ato-
moxetine for 6 months in patients who were responders
(defined as CGI score = 1 or 2 and >30% decrease in ADHD
or non-compliance behavior scores). Initial responders
Figure 8. Forest plot: Non-serious adverse events.
Figure 7. Forest plot outcome: Overall symptoms of ADHD (Clinical Global Improvement).















































































































continued to show sustained improvement in ADHD symp-
toms. Also, about a third of patients who were non-
responders to placebo responded to atomoxetine in the
open label extension study period of 6 months [Smith et al.,
2016]. This extension study aimed at the combined effect of
Parent Training and Atomoxetine on Non-compliant
behavior of children with ASD and ADHD. Authors con-
clude that atomoxetine continues to show beneficial effect
when continued for 6 months with similar non-serious
adverse effects (gastrointestinal symptoms and sleep prob-
lems) as seen in short-term treatment. Complicated design
of the trial and absence of any other RCT of 6 months dura-
tion precludes pooling of data for meta-analysis.
Out of the three included trials, one was a cross over
trial with the limitation of outcome assessor blinding
hence having high risk of bias. Two trials were sponsored
by pharmaceuticals hence there remains likely sources of
risk of bias which is unclear. In most outcomes we found
limitation of imprecision with the overall effect estimates
which lead us to judge the evidence to be low to very
low-quality hence future studies are likely to have an
impact on the effect estimates. Our findings based on
GRADE assessment are shown in detail in SOF (Table 2).
Strengths and Limitations of this Study
We developed the protocol during a workshop conducted
by Cochrane South Asia and it was registered in
PROSPERO with registration no. CRD42016041395. We
assessed risk of bias of the trials as per the recommenda-
tions of Cochrane Handbook of Systematic Reviews of
Interventions. We could not include unpublished trials in
the review which may be considered weakness of the
review.
Conclusions
Atomoxetine may be effective in causing improvement in
hyperactivity and inattention as also overall symptoms of
ADHD in children with ASD. There are higher reports of
gastrointestinal side effects and decreased sleep in ato-
moxetine group as compared to placebo which require
monitoring. However, the analysis did not find any sig-
nificant difference between atomoxetine and placebo in
causing serious side effects.
Compliance with Ethical Q14Standards
Ethical approval: This article does not contain any studies
with human participants performed by any of the authors.
Sources of Funding
None.
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Parent rated inattention
DSM-IV ADHD rating scale





– – SMD 0.53 lower (0.93 lower
to 0.12 lower)
Parent rated oppositional behavior
DSM-IV ADHD rating scale





– – SMD 0.09 lower (0.49 lower
to 0.31 higher)
Serious adverse events 193(3 RCTs)
LL
 LOWa,b RR 3 (0.32–27.76) Atomoxetine was not associated with
higher risk of serious side effects as
compared to placebo
Overall improvement in ADHD





RR 2.37 (1.38–4.06) 144 per
1,000
198 more per 1,000
(55 more to 442 more)
Parent stress and quality of life No studies have reported this outcome
Non-serious adverse events: nausea and






The risk ratio for all outcomes ranges from
1.79 to 1.91. with the 95% CI of
minimum (1.17 to maximum of 2.94)
Atomoxetine had a significantly higher
risk of non-serious side effects in all
of the listed outcomes compared to
placebo
*TheQ13 risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI, confidence interval; SMD, standardized mean difference; RR: risk ratio.
GRADE Working Group grades of evidence: High quality—we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality—we
are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low
quality—our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low quality—we have very little
confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
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